Europe’s old conventional-plant patent cases near zero—but gene-edited traits remain patentable
A new EPO report says the grandfathered backlog is down to about 35 cases and no post-2017 patent has covered a plant produced only by biological breeding. Technical interventions such as CRISPR remain patentable, subject to claim limits.
The story
Europe’s patent office says it has nearly completed a six-year clean-up of plant-patent cases caught between old and new law. A status report presented to the European Patent Organisation’s Committee on Patent Law on November 12 puts the remaining grandfathered examination backlog at about 35 cases. At the same time, it draws a durable line for future filings: plants produced only by crossing, selection or another essentially biological process are excluded, while plants created through a technical intervention such as targeted mutagenesis or CRISPR-Cas can remain patentable.
That distinction dates to July 1, 2017. Rule 28(2) of the European Patent Convention clarified that patents cannot cover plants or animals obtained exclusively through essentially biological processes. The EPO Enlarged Board’s 2020 G 3/19 opinion confirmed the exclusion but protected legitimate expectations by preventing it from being applied retroactively to patents already granted or applications filed, or claiming valid priority, before the cut-off date.
The transitional pool initially contained about 310 pending applications and 10 opposed patents, then rose to roughly 400 as appeal boards remitted cases and applicants filed divisionals. The EPO now says 13 applications have been refused, 108 withdrawn and 244 granted or proposed for grant, comprising 119 cases involving conventional plants and 125 involving technically produced plants. Approximately 35 examination cases remain, which the office describes as a ‘technical zero’ because divisionals and pending procedural steps prevent an immediate literal zero.
The office’s strongest compliance claim concerns newer applications. It says no patent has been granted for a filing or priority date on or after July 1, 2017 when the plant or animal was produced exclusively by an essentially biological breeding process. That exclusion also reaches reproductive material capable of generating the whole organism, including seeds and generally totipotent plant cells. A claim cannot avoid the rule merely by focusing on propagating material rather than the plant itself.
Technical production follows a different route. Genetic engineering, technically induced mutagenesis and targeted molecular methods such as CRISPR-Cas may support patentable subject matter, provided the invention also meets novelty, inventive-step, disclosure and other ordinary requirements. When the same characteristic could arise through either technical intervention or conventional breeding, the EPO requires a disclaimer limiting the claim to the technically produced product. Fourteen patents have now reached grant or proposed-grant stage with that disclaimer, seven more than in the previous report.
The new statistics show the scale but require care. Since 1982, the EPO counted about 9,805 published applications classified as relating to genetically modified plant processes or products; roughly 3,567 became patents, 5,048 were refused or withdrawn and 1,190 remained pending at the end of August. A separate conventional-plant and breeding classification contained about 1,378 published applications, including breeding tools, with 376 grants and 457 pending. Those classifications are not a count of active enforceable patents on market crops, and one filing can describe more than a commercial variety.
The report arrives as the European Union begins implementing Regulation 2026/1388 on new genomic techniques. The law did not adopt a general ban on patents for NGT plants. Instead, an applicant seeking NGT-1 status must disclose published patents or applications claiming the plant’s biological material in a public database and may volunteer a willingness to license on fair terms. A code of conduct, expert group and Commission assessment are meant to improve transparency and access, but regulatory approval as NGT-1 does not itself provide freedom to operate.
Independent analysis explains why that gap matters. A recent paper in the International Review of Intellectual Property and Competition Law argues that overlapping patents and plant-variety rights can make freedom-to-operate searches a bottleneck, especially when edited traits move quickly across varieties. The campaign group No Patents on Seeds takes a more critical view, alleging that claim drafting still reaches conventionally bred plants despite Rule 28(2). The EPO disputes that broader implication through its account of strict disclaimer enforcement; the disagreement has not yet produced a reported infringement or validity case identified by the office.
INNOVOX analysis: the backlog numbers show that Europe has mostly contained the retroactivity problem, not that plant-patent controversy is ending. The commercial frontier has shifted from direct claims to conventionally bred plants toward technical processes, edited sequences and traits that can appear in many later varieties. A disclaimer may narrow a patent on paper, but breeders still need reliable information about which rights cover their material and whether a licence is available on workable terms.
What to watch is how the system behaves outside examination. The remaining pre-2017 cases will close gradually, but the more consequential evidence will come from oppositions, licensing negotiations and any court test of a post-2017 disclaimer. The EU’s public patent information and licensing code will also need to connect a marketed seed or trait to the relevant rights with enough precision for smaller breeders to act. Without that operational layer, a legally clearer boundary may still leave an expensive search problem.
INNOVOX analysis
The EPO has largely cleared a transitional backlog without resolving the modern access problem. The decisive question is no longer whether ordinary crossing and selection can be patented directly; it is how broadly patents on edited sequences, traits and technical processes reach across later varieties. Transparency and licensing—not the headline exclusion—will determine whether smaller breeders can navigate that landscape.
What to watch
Watch the final grandfathered cases, oppositions to the 244 pre-2017 grants or proposed grants, and whether the EPO’s disclaimer language survives enforcement disputes. At EU level, the important tests are the NGT patent database, the licensing code of conduct due by January 2028 and the Commission’s assessment of breeders’ access to patented material.
